CagriSema (Cagrilintide 2.5 mg + Semaglutide 2.5 mg)

CagriSema is a combination research system incorporating Cagrilintide and Semaglutide. This formulation contains Cagrilintide 2.5 mg + Semaglutide 2.5 mg.

Cagrilintide is a long-acting amylin analogue investigated in research involving amylin receptor-related signaling, appetite and satiety regulation, food intake, and energy-balance mechanisms.

Semaglutide is a GLP-1 receptor agonist studied in connection with GLP-1 receptor signaling, glucose homeostasis, insulin and glucagon regulation, gastric emptying, and energy intake.

As a combined research formulation, CagriSema provides a system for investigating interactions between amylin and GLP-1 signaling pathways and their relationships with appetite regulation, energy homeostasis, glucose metabolism, and body-weight-related metabolic mechanisms.

The safety, efficacy, or appropriate human dosing of this specific 2.5 mg + 2.5 mg formulation should not be inferred from research or approved uses involving the individual components.

La livraison est facturée selon le nombre d'articles de la commande, aux mêmes tarifs pour toutes les destinations, et le montant exact s'affiche au moment du paiement, avant de payer. Expédition sous 1 jour ouvré.

Pas convaincu ? Renvoyez le produit sous 30 jours pour un remboursement intégral, même ouvert.